AstraZeneca sells cholesterol drug rights for up to $350m
(Sharecast News) - AstraZeneca said it had agreed to sell the rights to its cholesterol treatment Crestor to Germany's Grunenthal for up to $350m (£261m).
Read more(Sharecast News) - AstraZeneca said it had agreed to sell the rights to its cholesterol treatment Crestor to Germany's Grunenthal for up to $350m (£261m).
Read more(Adds details, updates prices, changes dateline)* World shares up 0.4% after strong European open* China factory activity growth hits 10-yr high in Nov* U.S. dollar weakens, risk-related currencies up* Oil slips after OPEC+ talks delay, copper upBy D...
Read moreLONDON, Nov 30 (Reuters) - British Prime Minister Boris Johnson said on Monday he hoped the leading COVID-19 vaccine candidates would be approved by regulators before Christmas."No vaccine has yet got MHRA (Medicines and Healthcare products Regula...
Read more* Vaccine 94.1% effective based on full trial results* Efficacy rate consistent across age, race and ethnicity* Moderna shares hit record high above $150* (Adds FDA comment on advisory group meeting)By Julie Steenhuysen and Michael ErmanNov 30 (Reut...
Read more* Vaccine 94.1% effective based on full trial results* Efficacy rate consistent across age, race and ethnicity* Moderna shares hit record high above $150* (Adds that Moderna has applied for US emergency authorization)By Julie Steenhuysen and Michael...
Read more* Vaccine 94.1% effective based on full trial results* Efficacy rate consistent across age, race and ethnicity* Moderna shares hit new record high above $150* FACTBOX-Moderna's mRNA coronavirus vaccine: (Updates Moderna shares)By Julie Steenhuysen a...
Read more(Adds expert reaction)By Julie Steenhuysen and Michael ErmanNov 30 (Reuters) - Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% e...
Read more* Vaccine 94.1% effective based on full trial results* Efficacy rate consistent across age, race and ethnicity* Moderna shares set to hit new record high* FACTBOX-Moderna's mRNA coronavirus vaccine: (Adds more expert comment, Moderna shares)By Julie...
Read moreDec 11 (Reuters) - Pfizer Inc and BioNTech SE received U.S. regulatory authorization for their COVID-19 vaccine on Friday, making it the first inoculation against the new coronavirus to get a regulatory green light in the United States.The follow...
Read moreDec 11 (Reuters) - Britain became the first country to roll out the COVID-19 vaccine developed by Pfizer Inc and BioNTech on Dec. 8 after final late-stage trial results showed it was 95% effective in preventing the disease.The following is what we...
Read moreDec 11 (Reuters) - Britain became the first country to roll out the COVID-19 vaccine developed by Pfizer Inc and BioNTech on Dec. 8 after final late-stage trial results showed it was 95% effective in preventing the disease.The following is what we...
Read moreUK BROKER RATINGS SUMMARY: UBS Upgrades AstraZeneca To Neutral
Read moreAstraZeneca's Forxiga Approved For Use In Japan On Robust Test Results
Read more(Sharecast News) - AstraZeneca announced on Monday that 'Forxiga', or dapagliflozin, has been approved in Japan for the treatment of patients with chronic heart failure, who are receiving standard-of-care.
Read moreBy Manoj Kumar and Euan RochaNEW DELHI/MUMBAI, Nov 29 (Reuters) - The Indian Council of Medical Research (ICMR) is assisting an inquiry into an alleged adverse reaction during AstraZeneca's COVID-19 vaccine trial, but has found no reason to recomm...
Read more